Director's large stake reduction: Social media users are closely examining a significant share sale by a Kymera Therapeutics director involving millions of shares at around $98 per share. This move has prompted discussions on potential implications for company leadership confidence amid ongoing clinical developments.
Pipeline progress highlighted: Analysts and observers note positive data from Phase 1b and 2b trials for KT-621 targeting STAT6 in conditions like atopic dermatitis and asthma, with projections for substantial peak sales. Comparisons to established therapies such as Dupixent fuel debates on market expansion potential for an oral alternative.
Community partnerships noted: Recent announcements of Kymera joining industry councils focused on asthma and allergies have drawn attention, with participants viewing this as a step toward broader patient engagement and research collaboration in the immunology space.
Note: This discussion summary was generated from an AI condensation of post data.
Kymera Therapeutics Insider Trading Activity
Kymera Therapeutics insiders have traded $KYMR stock on the open market 110 times in the past 6 months. Of those trades, 0 have been purchases and 110 have been sales.
Here’s a breakdown of recent trading of $KYMR stock by insiders over the last 6 months:
- BRUCE BOOTH has made 0 purchases and 40 sales selling 525,490 shares for an estimated $49,986,641.
- JEREMY G CHADWICK (Chief Operating Officer) has made 0 purchases and 29 sales selling 193,968 shares for an estimated $15,599,493.
- NELLO MAINOLFI (Chief Executive Officer) has made 0 purchases and 10 sales selling 90,000 shares for an estimated $7,485,129.
- NOAH GOODMAN (Chief Business Officer) has made 0 purchases and 6 sales selling 14,111 shares for an estimated $1,266,512.
- BRUCE N. JACOBS (Chief Financial Officer) has made 0 purchases and 7 sales selling 12,471 shares for an estimated $1,091,230.
- ELENA RIDLOFF has made 0 purchases and 3 sales selling 12,000 shares for an estimated $1,024,660.
- JARED GOLLOB (Chief Medical Officer) has made 0 purchases and 7 sales selling 10,508 shares for an estimated $916,668.
- PAMELA ESPOSITO has made 0 purchases and 8 sales selling 10,500 shares for an estimated $789,668.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Kymera Therapeutics Hedge Fund Activity
We have seen 137 institutional investors add shares of Kymera Therapeutics stock to their portfolio, and 121 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,771,376 shares (+31.0%) to their portfolio in Q1 2026, for an estimated $230,827,907
- VANGUARD GROUP INC added 845,922 shares (+15.6%) to their portfolio in Q4 2025, for an estimated $65,821,190
- WELLINGTON MANAGEMENT GROUP LLP removed 523,246 shares (-11.9%) from their portfolio in Q1 2026, for an estimated $43,581,159
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 514,388 shares (-84.2%) from their portfolio in Q4 2025, for an estimated $40,024,530
- UBS GROUP AG added 286,820 shares (+38.9%) to their portfolio in Q1 2026, for an estimated $23,889,237
- BNP PARIBAS FINANCIAL MARKETS added 277,073 shares (+3149.3%) to their portfolio in Q1 2026, for an estimated $23,077,410
- GEODE CAPITAL MANAGEMENT, LLC added 227,961 shares (+16.1%) to their portfolio in Q1 2026, for an estimated $18,986,871
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Kymera Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $KYMR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/03/2026
To track analyst ratings and price targets for Kymera Therapeutics, check out Quiver Quantitative's $KYMR forecast page.
Kymera Therapeutics Price Targets
Multiple analysts have issued price targets for $KYMR recently. We have seen 8 analysts offer price targets for $KYMR in the last 6 months, with a median target of $124.0.
Here are some recent targets:
- Edward Nash from Canaccord Genuity set a target price of $106.0 on 05/06/2026
- Faisal Khurshid from Jefferies set a target price of $110.0 on 03/16/2026
- David Dai from UBS set a target price of $128.0 on 03/03/2026
- Sudan Loganathan from Stephens & Co. set a target price of $100.0 on 03/02/2026
- Geoff Meacham from Citigroup set a target price of $120.0 on 03/02/2026
- Biren Amin from Piper Sandler set a target price of $140.0 on 02/26/2026
- Jeet Mukherjee from BTIG set a target price of $134.0 on 02/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
